ATE524460T1 - Pyridon-gpr119-g-protein-gekoppelte rezeptoragonisten - Google Patents

Pyridon-gpr119-g-protein-gekoppelte rezeptoragonisten

Info

Publication number
ATE524460T1
ATE524460T1 AT08781867T AT08781867T ATE524460T1 AT E524460 T1 ATE524460 T1 AT E524460T1 AT 08781867 T AT08781867 T AT 08781867T AT 08781867 T AT08781867 T AT 08781867T AT E524460 T1 ATE524460 T1 AT E524460T1
Authority
AT
Austria
Prior art keywords
gpr119
pyridone
protein
receptor agonists
coupled receptor
Prior art date
Application number
AT08781867T
Other languages
German (de)
English (en)
Inventor
Dean A Wacker
Karen A Rossi
Ying Wang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE524460T1 publication Critical patent/ATE524460T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
AT08781867T 2007-07-17 2008-07-16 Pyridon-gpr119-g-protein-gekoppelte rezeptoragonisten ATE524460T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95016207P 2007-07-17 2007-07-17
PCT/US2008/070101 WO2009012275A1 (en) 2007-07-17 2008-07-16 Pyridone gpr119 g protein-coupled receptor agonists

Publications (1)

Publication Number Publication Date
ATE524460T1 true ATE524460T1 (de) 2011-09-15

Family

ID=39864683

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08781867T ATE524460T1 (de) 2007-07-17 2008-07-16 Pyridon-gpr119-g-protein-gekoppelte rezeptoragonisten
AT08781868T ATE540945T1 (de) 2007-07-17 2008-07-16 Verfahren zur modulation des gpr119-g- proteingekoppelten rezeptors und ausgewählte verbindungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT08781868T ATE540945T1 (de) 2007-07-17 2008-07-16 Verfahren zur modulation des gpr119-g- proteingekoppelten rezeptors und ausgewählte verbindungen

Country Status (26)

Country Link
US (6) US8003796B2 (enExample)
EP (2) EP2170864B1 (enExample)
JP (3) JP5301539B2 (enExample)
KR (2) KR20100051814A (enExample)
CN (3) CN101801956B (enExample)
AR (2) AR067568A1 (enExample)
AT (2) ATE524460T1 (enExample)
AU (2) AU2008276057B2 (enExample)
BR (2) BRPI0814428A2 (enExample)
CA (2) CA2693439A1 (enExample)
CL (2) CL2008002111A1 (enExample)
CO (1) CO6160315A2 (enExample)
CY (2) CY1112151T1 (enExample)
DK (2) DK2173737T3 (enExample)
EA (2) EA018709B1 (enExample)
ES (2) ES2378914T3 (enExample)
HR (2) HRP20110806T1 (enExample)
IL (1) IL228120A0 (enExample)
NZ (2) NZ582664A (enExample)
PE (2) PE20090449A1 (enExample)
PL (2) PL2170864T3 (enExample)
PT (2) PT2170864E (enExample)
SI (2) SI2170864T1 (enExample)
TW (2) TW200904439A (enExample)
WO (2) WO2009012277A1 (enExample)
ZA (2) ZA201000151B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158652B2 (en) * 2004-12-01 2012-04-17 Msd K.K. Substituted pyridone derivative
CN101668756A (zh) 2007-05-04 2010-03-10 百时美施贵宝公司 [6,6]和[6,7]-双环gpr119 g蛋白偶合受体激动剂
HRP20110806T1 (hr) * 2007-07-17 2011-11-30 Bristol-Myers Squibb Company Agonisti piridon gpr119 g protein-vezanih receptora
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
TW201006821A (en) * 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
CA2730593A1 (en) * 2008-07-16 2010-01-21 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
US8815876B2 (en) 2008-07-16 2014-08-26 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and methods of use thereof
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
WO2010106457A2 (en) * 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
US8293729B2 (en) 2009-06-24 2012-10-23 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
US8481731B2 (en) 2009-06-24 2013-07-09 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
PH12012501853A1 (en) 2010-04-08 2013-01-07 Bristol Myers Squibb Co Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators
WO2011140161A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
EA201270778A1 (ru) 2010-05-06 2013-04-30 Бристол-Майерс Сквибб Компани Бициклические гетероарильные аналоги в качестве модуляторов рецептора gpr119
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
PH12013500671A1 (en) 2010-10-08 2018-04-11 Cadila Healthcare Ltd Novel gpr 119 agonists
CA2819889C (en) 2010-12-06 2020-12-15 Confluence Life Sciences, Inc. Substituted pyridinone-pyridinyl compounds
US9359300B2 (en) 2010-12-06 2016-06-07 Confluence Life Sciences, Inc. Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
JP5935154B2 (ja) * 2011-03-14 2016-06-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｐｒ１１９モジュレーターとしてのｎ−シクロプロピル−ｎ−ピペリジニルベンズアミド
WO2012170867A1 (en) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9174965B2 (en) 2012-05-16 2015-11-03 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators
EP2872127A1 (en) 2012-07-11 2015-05-20 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
PT2921489T (pt) * 2012-11-13 2017-12-01 Nissan Chemical Ind Ltd Composto de 2-piridona
CN102993088A (zh) * 2012-12-31 2013-03-27 东华大学 一种4-羟基-2-吡啶酮的制备方法
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
PT3003039T (pt) 2013-06-07 2021-03-04 Aclaris Therapeutics Inc Compostos piridinona-piridinilo substituídos com metil/fluoro-piridinil-metoxilo e compostos piridinona-pirimidinilo substituídos com fluoro-pirimidinil-metoxilo
ES2712211T3 (es) 2013-06-20 2019-05-09 Bayer Cropscience Ag Derivados de arilsulfuro y arilsulfóxido acaricidas e insecticidas
WO2014202510A1 (de) 2013-06-20 2014-12-24 Bayer Cropscience Ag Arylsulfid- und arylsulfoxid-derivate als akarizide und insektizide
AR096816A1 (es) 2013-07-08 2016-02-03 Bayer Cropscience Ag Derivados de arilsulfuro y arilsulfóxido de seis miembros enlazados con c-n como agentes para combatir parásitos
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
EP2929883A1 (en) 2014-04-08 2015-10-14 Institut Pasteur Pyrazole derivatives as dihydroorotate dehydrogenase (DHODH) inhibitors
WO2016040789A1 (en) 2014-09-11 2016-03-17 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
US10399948B2 (en) 2015-02-10 2019-09-03 Vanderbilt University Negative allosteric modulators of metabotropic glutamate receptor 3
JP6578116B2 (ja) * 2015-03-25 2019-09-18 公益財団法人相模中央化学研究所 一置換（フルオロアルキル）エチレン類及びその製造方法
US10865194B2 (en) 2017-11-03 2020-12-15 Fondazione Istituto Italiano Di Tecnologia Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
CN115666566A (zh) 2020-03-27 2023-01-31 阿克拉瑞斯治疗股份有限公司 用于免疫病况的治疗的mk2途径抑制剂的口服组合物
AU2021275038A1 (en) 2020-05-19 2022-12-22 Kallyope, Inc. AMPK activators
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
WO2022081573A1 (en) * 2020-10-12 2022-04-21 University Of Tennessee Research Foundation Transient receptor potential canonical 3 inhibitors and methods of use thereof
CN115504927A (zh) * 2022-08-15 2022-12-23 广西中医药大学 4-甲基-2-对甲苯基-6-羰基吡啶-3-甲酸及其制备方法和用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3826643A (en) 1967-08-07 1974-07-30 American Cyanamid Co Method of controlling undesirable plant species using 3-nitropyridines
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5488064A (en) 1994-05-02 1996-01-30 Bristol-Myers Squibb Company Benzo 1,3 dioxole derivatives
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5491134A (en) 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5770615A (en) 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US6566384B1 (en) 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
UA57811C2 (uk) 1997-11-21 2003-07-15 Пфайзер Продактс Інк. Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності
KR20010083092A (ko) 1998-07-06 2001-08-31 스티븐 비. 데이비스 이중 안지오텐신 엔도텔린 수용체 길항제로서의 비페닐술폰아미드
EP1058549A4 (en) 1998-12-23 2003-11-12 Bristol Myers Squibb Pharma Co FACTOR Xa OR THROMBIN INHIBITORS
CA2413241A1 (en) 2000-06-29 2002-01-10 Bristol-Myers Squibb Pharma Company Thrombin or factor xa inhibitors
ES2280435T3 (es) 2000-12-01 2007-09-16 Astellas Pharma Inc. Metodo de exploracion de remedios para la diabetes.
CA2469435A1 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
PT1490064E (pt) * 2002-02-14 2009-12-28 Pharmacia Corp Piridinonas substituídas como moduladores de p38 map-quinase
BRPI0406761A (pt) 2003-01-14 2005-12-20 Arena Pharm Inc Derivados de arila e heteroarila 1,2,3-trissubstituìdos como moduladores do metabolismo e a profilaxia e tratamento de distúrbios relacionados a estes tais como diabetes e hiper-glicemia
JP2006518763A (ja) 2003-02-24 2006-08-17 アリーナ ファーマシューティカルズ， インコーポレイテッド グルコース代謝のモジュレーターとしてのフェニル−およびピリジルピペリジン誘導体
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
US7003597B2 (en) * 2003-07-09 2006-02-21 International Business Machines Corporation Dynamic reallocation of data stored in buffers based on packet size
CN100509798C (zh) * 2003-07-11 2009-07-08 艾尼纳制药公司 作为新陈代谢调节剂的三取代芳基和杂芳基衍生物以及预防和治疗与其相关之病症
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
AR045697A1 (es) * 2003-07-14 2005-11-09 Arena Pharm Inc Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo
US20070088163A1 (en) 2003-09-12 2007-04-19 Kemia, Inc. Modulators of calcitonin and amylin activity
CN1930126A (zh) * 2004-03-05 2007-03-14 万有制药株式会社 吡啶酮衍生物
MXPA06010345A (es) 2004-03-17 2007-06-19 7Tm Pharma As Agonistas de receptor selectivo de y4 para intervenciones terapeuticas.
PL1756096T3 (pl) 2004-05-03 2010-01-29 Hoffmann La Roche Pochodne indolilowe jako modulatory wątrobowych receptorów X
MXPA06014129A (es) 2004-06-04 2007-03-07 Arena Pharm Inc Derivados de arilo y heteroarilo sustituidos como moduladores del metabolismo y profilaxis y tratamiento de trastornos relacionados con los mismos.
US8193359B2 (en) 2004-12-24 2012-06-05 Prosidion Limited G-protein coupled receptor agonists
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
JP5349960B2 (ja) 2005-06-23 2013-11-20 エモリー ユニバーシティー 腫瘍画像化のためのアミノ酸類似体の立体選択的合成
EP1907383A1 (en) * 2005-06-30 2008-04-09 Prosidion Limited Gpcr agonists
US20090221644A1 (en) 2005-06-30 2009-09-03 Stuart Edward Bradley Gpcr Agonists
CN101668756A (zh) 2007-05-04 2010-03-10 百时美施贵宝公司 [6,6]和[6,7]-双环gpr119 g蛋白偶合受体激动剂
EP2152707B1 (en) 2007-05-04 2012-06-20 Bristol-Myers Squibb Company [6,5]-bicyclic gpr119 g protein-coupled receptor agonists
HRP20110806T1 (hr) * 2007-07-17 2011-11-30 Bristol-Myers Squibb Company Agonisti piridon gpr119 g protein-vezanih receptora

Also Published As

Publication number Publication date
PL2173737T3 (pl) 2012-06-29
KR20100045471A (ko) 2010-05-03
CY1112751T1 (el) 2016-02-10
CA2693439A1 (en) 2009-01-22
US8232404B2 (en) 2012-07-31
AU2008276057A1 (en) 2009-01-22
CY1112151T1 (el) 2015-12-09
US8178561B2 (en) 2012-05-15
HRP20120221T1 (hr) 2012-04-30
JP2010533727A (ja) 2010-10-28
PT2173737E (pt) 2012-03-19
AR067569A1 (es) 2009-10-14
WO2009012275A9 (en) 2010-03-11
PE20090888A1 (es) 2009-07-15
BRPI0815097A2 (pt) 2018-07-24
EP2173737A1 (en) 2010-04-14
AU2008276055A1 (en) 2009-01-22
ES2371515T3 (es) 2012-01-04
CA2693444A1 (en) 2009-01-22
WO2009012275A1 (en) 2009-01-22
DK2173737T3 (da) 2012-05-07
US7928230B2 (en) 2011-04-19
JP2010533726A (ja) 2010-10-28
US20090023702A1 (en) 2009-01-22
ZA201000151B (en) 2011-03-30
HK1136298A1 (en) 2010-06-25
JP5318867B2 (ja) 2013-10-16
CN103550218A (zh) 2014-02-05
EA018709B1 (ru) 2013-10-30
CL2008002110A1 (es) 2008-10-24
EP2170864A1 (en) 2010-04-07
BRPI0814428A2 (pt) 2015-01-06
PE20090449A1 (es) 2009-04-18
HK1143136A1 (en) 2010-12-24
EP2170864B1 (en) 2011-09-14
PL2170864T3 (pl) 2012-02-29
PT2170864E (pt) 2011-11-25
EA201000211A1 (ru) 2010-06-30
JP2013237680A (ja) 2013-11-28
HRP20110806T1 (hr) 2011-11-30
TW200904440A (en) 2009-02-01
AU2008276057B2 (en) 2013-01-31
TW200904439A (en) 2009-02-01
ZA201000326B (en) 2011-03-30
CN101801957A (zh) 2010-08-11
IL228120A0 (en) 2013-09-30
ES2378914T3 (es) 2012-04-19
US8513424B2 (en) 2013-08-20
CN101801956B (zh) 2013-11-20
SI2170864T1 (sl) 2012-04-30
AR067568A1 (es) 2009-10-14
NZ582661A (en) 2012-03-30
US20120258959A1 (en) 2012-10-11
US8003796B2 (en) 2011-08-23
NZ582664A (en) 2012-03-30
US20110245227A1 (en) 2011-10-06
US20090042919A1 (en) 2009-02-12
CL2008002111A1 (es) 2008-10-24
JP5301539B2 (ja) 2013-09-25
SI2173737T1 (sl) 2012-05-31
EP2173737B1 (en) 2012-01-11
WO2009012277A1 (en) 2009-01-22
ATE540945T1 (de) 2012-01-15
CN101801956A (zh) 2010-08-11
US20110190327A1 (en) 2011-08-04
CO6160315A2 (es) 2010-05-20
EA201000210A1 (ru) 2010-06-30
AU2008276055B2 (en) 2013-01-31
EA016595B1 (ru) 2012-06-29
KR20100051814A (ko) 2010-05-18
DK2170864T3 (da) 2012-01-16
US20120232048A1 (en) 2012-09-13

Similar Documents

Publication Publication Date Title
ATE524460T1 (de) Pyridon-gpr119-g-protein-gekoppelte rezeptoragonisten
HUS2200033I1 (hu) CGRP receptor antagonisták
LTPA2020513I1 (lt) S1P receptoriaus agonisto dozavimas
BRPI0820447A2 (pt) Agonistas do receptor de glicocorticóides
EP1981902A4 (en) ANTAGONISTS OF NOGO RECEPTORS
BRPI0806500A2 (pt) Agonistas gpcr de piperidina
ATE531710T1 (de) Piperidin-gpcr-agonisten
GB0720390D0 (en) G-Protein coupled receptor agonists
EP2350060A4 (en) Melanocortin receptor AGONISTS
GB0720389D0 (en) G-Protein Coupled Receptor Agonists
BRPI0910118A2 (pt) antagonistas de receptores do glucagon
EP2150115A4 (en) CYCLOPROPYLPYRROLIDINOREXIN Receptor Antagonists
BRPI0913930A2 (pt) antagonistas de receptores de prostaglandinas d2
GB0607196D0 (en) G-protein coupled receptor agonists
EP2173174A4 (en) FARNESOID X RECEPTOR AGONISTS
EP2079307A4 (en) Farnesoid X RECEPTOR AGONISTS
EP2170072A4 (en) Farnesoid X RECEPTOR AGONISTS
ATE535521T1 (de) Hydroxymethyl-pyrrolidine als beta-3-adrenerge rezeptoragonisten
DK2081951T3 (da) Progesteron-receptorantagonister
EP2490709A4 (en) PEPTIDIC GLP-2 AGONISTS
ATE509022T1 (de) Nikotin-acetylcholin-rezeptorsubtyp-selektive diazabicycloalkanamide
EP2151236A4 (en) G-PROTEIN-CONJUGATED RECEPTOR AGONIST
DK2252581T3 (da) Kappa-selektiv opioidreceptorantagonist
BRPI0807911A2 (pt) Agonistas de alfa2c adrenorreceptor
DK2009992T3 (da) Il-8 receptor-antagonister

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2170864

Country of ref document: EP